The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy

Sponsor
Huashan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04367116
Collaborator
(none)
10
1
1
30
0.3

Study Details

Study Description

Brief Summary

The study is an open-label, prospective, single-arm, unicentral (Huashan Hospital Department of Neurology/ Neurosurgery) and exploratory clinical trial. Subjects will be enrolled from Parkinson's disease and Movement Disorder specialized outpatient department of Neurology in Huashan Hospital and network platform of chronic diseases. Spinal Cord Stimultion (SCS) will be performed in department of Neurosurgery and cerebral metabolism will be assessed in PET center of Huashan Hospital. Specialists in Neurology will follow up 3 months to record any unsafe incidents of progressive supranuclear palsy patients after the SCS surgery to evaluate safety. Meanwhile, improvement in gait disorder (including 10MWT and TUG test score) will be measured to evaluate efficacy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Spinal Cord Stimulation
N/A

Detailed Description

The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy is an open-label, prospective, single-arm, unicentral and exploratory clinical trial.

In the screening stage, patients clinically and radiologically diagnosed as progressive supranuclear palsy with prominent gait disturbance will be enrolled. Then comprehensive evaluations and spinal cord stimulation will be performed on patients eligible for stimulation. In the subsequent process of neuromodulation, changes of clinical presentations and cerebral metabolism of participants will be assessed. Any unsafe incidents in process will be recorded in detail.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
The assessors were blind to the stimulation status of the patient.
Primary Purpose:
Treatment
Official Title:
The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: spinal cord stimulation

the spinal cord stimulation was performed and operated

Procedure: Spinal Cord Stimulation
Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.

Outcome Measures

Primary Outcome Measures

  1. Safety of Spinal Cord Stimulation [3 months]

    Safety evaluation will be performed 3 months after Spinal Cord Stimualtion

  2. Efficacy of Spinal Cord Stimulation on walk gait. [3 months after Spinal Cord Stimualtion.]

    The change of 10 Meter Walk Test (10MWT) scores. The 10MWT recorded the time to finish the test, and the maximum time is 5 minutes. The longer time suggest more severe condition.

  3. Efficacy of Spinal Cord Stimulation on walk time. [3 months after Spinal Cord Stimualtion.]

    Changes of the Time Up & Go (TUG) test score. TUG test recorded the time to finish the test, the minimum time is 0 and the maximum time is 5 minutes. The longer time suggest more severe condition.

Secondary Outcome Measures

  1. Alteration of cerebral metabolism in 18F-FDG-PET imaging [6 months]

    Alteration of cerebral metabolism in 18F-FDG-PET imaging 6 months after Spinal Cord Stimualtion

  2. Alteration of gait, balance and motor score [1 month, 6 months]

    Alteration of gait, balance and motor score 1 month, 6 months after Spinal Cord Stimualtion. The New Freezing of Gait Questionnaire (NFOG-Q) will be assessed, with the minimum score to be 0 and the maximum score to be 30 scores, with higher scores suggest more severe condition.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Clinical diagnosis is Progressive Supranuclear Palsy according to International Movement Disorder society criteria for Progressive Supranuclear Palsy (2017).

2.18FDG-PET imaging was completed within three months before the operation, and the imaging results were consistent with characteristics of Progressive Supranuclear Palsy, supporting the clinical diagnosis of Progressive Supranuclear Palsy.

  1. The clinical manifestation is prominent gait balance disorder with "freezing gait", "turn difficulties" and "feet like a stick on the ground", "instabillity" and a fall history in the nearly 6 months (fall number less than or equal to 3 times).Or the researchers observe the existence of gait balance disorder, but patients can still walk without using external things with new freezing gait questionnaire survey more than 1 minute.

4.Those who fully understand the research and sign the informed consent.

Exclusion Criteria:
  1. Severe mental symptoms or depression state.

  2. Severe cognitive dysfunction with MMSE less than 20.

  3. Severe loss of postural reflexes (inability to stand and work independently) and depend on a walker or wheelchair.

  4. Depend on nasal feeding tube.

  5. Female in pregnant state when grouped.

  6. Clear and definite history of neurological diseases (stroke, trauma, tumor, hydrocephalus.

  7. Complicated with severe heart, liver or renal diseases.

  8. Clear and definite contraindications for surgery, electrical stimulation and PET examination.

  9. Unsuitable for surgery according to evaluation before the surgery.

  10. Other conditions that researchers think unsuitable surgery.

  11. Those who participant in other clinical trials at the same time.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huashan Hospital Shanghai Shanghai China 200040

Sponsors and Collaborators

  • Huashan Hospital

Investigators

  • Study Director: Feng-Tao Liu, MD, Huashan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jian Wang, Professor of neurology, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT04367116
Other Study ID Numbers:
  • KY2019-506
First Posted:
Apr 29, 2020
Last Update Posted:
Mar 25, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2022